OCUL - Ocular Therapeutix, Inc.
NEXT EARNINGS:
May 11, 2026
EPS Est: $-0.32
|
Rev Est: $12.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$27.00
DETAILS
HIGH:
$31.00
LOW:
$21.00
MEDIAN:
$29.00
CONSENSUS:
$27.00
UPSIDE:
201.51%
Market Cap:
1.95B
Volume:
6,238,409
Avg Volume:
5,557,883
52 Week Range:
5.785-16.44
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.90
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
274
IPO Date:
2014-07-25
EPS (TTM):
-1.42
P/E Ratio:
-8.55
Revenue (TTM):
51.82M
Total Assets:
808.06M
Total Debt:
79.78M
Cash & Equiv:
737.06M
Rev Growth (5Y):
24.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-33.6%
Debt/Equity:
0.12
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-05 | $-0.29 | $-0.33 | +12.1% | $13.2M | $16.1M | -17.8% |
| 2025-11-04 | $-0.37 | $-0.39 | +5.1% | $14.5M | $16.1M | -9.9% |
| 2025-08-05 | $-0.39 | $-0.35 | -11.4% | $13.5M | $14.6M | -7.6% |
| 2025-05-05 | $-0.37 | $-0.29 | -27.6% | $10.6M | $13.1M | -18.8% |
| 2025-03-03 | $-0.29 | $-0.24 | -20.8% | $17.1M | $17.1M | -0.2% |
| 2024-11-14 | $-0.26 | $-0.23 | -13.0% | $15.4M | $16.9M | -8.7% |
| 2024-08-07 | $-0.24 | $-0.22 | -9.1% | $16.4M | $15.8M | +3.9% |
| 2024-05-07 | $-0.24 | $-0.18 | -33.3% | $14.7M | $15.4M | -4.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.82M | 63.72M | 58.44M | 51.49M | 43.52M | 17.40M | 4.23M | 1.99M | 1.92M | 1.89M | 1.75M | 772,000 |
| Net Income | (265.94M) | (193.51M) | (80.74M) | (71.04M) | (6.55M) | (155.64M) | (86.37M) | (57.69M) | (63.39M) | (44.70M) | (39.75M) | (28.65M) |
| EPS | -1.42 | -1.22 | -1.09 | -1.04 | -1.05 | -2.56 | -1.91 | -1.57 | -2.20 | -1.80 | -1.71 | -2.69 |
| Total Assets | 808.06M | 457.94M | 252.06M | 149.29M | 204.89M | 261.86M | 78.74M | 73.04M | 55.43M | 74.94M | 110.31M | 78.19M |
| Total Debt | 79.78M | 75.78M | 83.39M | 64.28M | 58.98M | 58.44M | 59.34M | 24.79M | 18.02M | 15.64M | 15.27M | 14.87M |
| Cash & Equivalents | 737.06M | 392.10M | 195.81M | 102.30M | 164.16M | 228.06M | 54.44M | 54.06M | 41.54M | 32.94M | 30.78M | 37.39M |
| Operating Cash Flow | (204.88M) | (134.68M) | (70.23M) | (59.60M) | (65.55M) | (53.55M) | (77.58M) | (49.23M) | (50.47M) | (34.00M) | (33.74M) | (20.50M) |
| Free Cash Flow | (216.89M) | (135.97M) | (76.32M) | (63.32M) | (66.74M) | (54.40M) | (79.82M) | (51.12M) | (58.73M) | (35.92M) | (35.52M) | (21.76M) |
| FCF per Share | -1.16 | -0.86 | -0.96 | -0.82 | -0.87 | -0.90 | -1.76 | -1.34 | -2.04 | -1.45 | -1.53 | -2.04 |
| Book Value | 654.31M | 315.34M | 91.13M | 35.38M | 88.00M | 76.09M | (3.63M) | 35.88M | 26.15M | 52.01M | 89.59M | 58.70M |
| Cash & ST Investments | 737.06M | 392.10M | 195.81M | 102.30M | 164.16M | 228.06M | 54.44M | 54.06M | 41.54M | 68.14M | 105.06M | 74.83M |
| ROC Equity | -0.41 | -0.61 | -0.89 | -2.01 | -0.07 | -2.05 | N/A | -1.61 | -2.42 | -0.86 | -0.44 | -0.49 |